Pranlukast is a potent, selective, and competitive leukotriene receptor antagonist (LTRA) that has become a staple in the management of chronic respiratory conditions. By specifically blocking the action of cysteinyl leukotrienes—inflammatory mediators that cause airway constriction, mucus production, and swelling—Pranlukast helps maintain open airways and reduces the frequency of acute episodes. Unlike rescue inhalers, it is designed for long-term prophylaxis, providing a steady baseline of protection for patients who suffer from persistent symptoms that interfere with daily life and sleep.

The Pranlukast Market continues to see steady demand as healthcare providers seek effective oral alternatives to inhaled corticosteroids for specific patient phenotypes. The drug's ability to inhibit airway remodeling and suppress vascular permeability makes it a valuable asset in the treatment of chronic bronchial asthma and allergic rhinitis. As researchers explore its secondary benefits in reducing systemic inflammation, the market is expanding beyond its traditional strongholds, attracting interest from pharmaceutical manufacturers looking to diversify their respiratory portfolios with established, well-tolerated molecules.